OUTSMARTING TUMOR ADAPTATION
Cancer adapts to survive therapy. We are making adaptation its weakness.
AtG Therapeutics is developing first-in-class TA-1 inhibitors combined with a biomarker-enriched patient selection strategy to target adaptive dependencies in therapy-resistant solid tumors.
Our approach
At AtG we turn tumor adaptation into a therapeutic vulnerability.
Systemic therapies can initially control disease, but tumors can rewire survival pathways under treatment pressure. These adaptive states create new dependencies that can be therapeutically exploited.
01 – Therapeutic pressure
Treatment pressure activates stress-response programs.
02 – Tumor adaptation
Tumor cells engage alternative survival routes.
03 – TA-1 Dependency
TA-1 helps sustain the adaptive tumor state under pressure.
04 – Adaptive collapse
TA-1 inhibition is designed to close escape routes and arrest tumor growth.
Our lead program targets TA-1, an intracellular regulator of the adaptive tumor state. We are developing first-in-class TA-1 inhibitors together with a biomarker-enriched strategy to identify tumors most likely to depend on this biology under therapeutic pressure.
Drug + Biomarker
Drug the adaptation. Identify the dependency. Select the patient.
AtG is developing first-in-class intracellular TA-1 inhibitors designed to disrupt adaptive survival biology in therapy-resistant tumors.
A blood-based TA-1 biomarker strategy is being developed to enrich for patients whose tumors are most likely to depend on TA-1 biology, supporting a biomarker-enriched clinical development strategy and translational monitoring.
INITIAL DEVELOPMENT FOCUS
LEAD INDICATION
RCC
RENAL CELL CARCINOMA
EXPANSION
CRC
COLORECTAL CANCER
EXPANSION
HCC
HEPATOCELLULAR CARCINOMA
ATG Therapeutics
Built to translate tumor-adaptation biology into medicines.
AtG combines expertise in tumor biology, medicinal chemistry, translational pharmacology, drug development, biomarker development and biotech strategy, supported by an international network of scientific, clinical and industry advisors.
01 TUMOR BIOLOGY
02 MEDICINAL CHEMISTRY
03 TRANSLATIONAL PHARMACOLOGY
04 BIOMARKER DEVELOPMENT
05 DRUG DEVELOPMENT
06 BIOTECH STRATEGY
Partners & network
Supported by an international scientific and biotech network.
AtG welcomes conversations with investors, pharmaceutical partners, translational collaborators and scientific leaders interested in advancing biomarker-guided therapies for treatment-resistant cancer
news & insights
Latest from AtG
Scientific progress, development milestones and perspectives on tumor adaptation, biomarker-guided oncology and the TA-1 program.
- Events
AtG Therapeutics is joining the Catalonia Health BBQ2026, the annual summer gathering of the Catalan biomedical ecosystem organized by Catalonia.health. The event takes place on Thursday, July 16, 2026, from 19:30h at the
- Events
AtG Therapeutics and its COO Gabriela Jiménez Valerio, PhD, received the “Premi Salut” (Health Award) at the 8th edition of the Premis Emprenedors Digitals del Revolució CatRàdio 2026, held at the Antiga Fàbrica
Outsmarting tumor adaptation – together.
Help us advance a new therapeutic strategy for treatment-resistant cancer.